Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 111

1.

Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia.

Mohammadi A, Rashidi E, Amooeian VG.

Psychiatry Res. 2018 Jul;265:25-38. doi: 10.1016/j.psychres.2018.04.036. Epub 2018 Apr 13. Review.

PMID:
29680514
2.

A gene-based review of RGS4 as a putative risk gene for psychiatric illness.

Schwarz E.

Am J Med Genet B Neuropsychiatr Genet. 2018 Mar;177(2):267-273. doi: 10.1002/ajmg.b.32547. Epub 2017 May 24. Review.

PMID:
28544755
3.

Expression of the Longest RGS4 Splice Variant in the Prefrontal Cortex Is Associated with Single Nucleotide Polymorphisms in Schizophrenia Patients.

Ding L, Styblo M, Drobná Z, Hegde AN.

Front Psychiatry. 2016 Feb 29;7:26. doi: 10.3389/fpsyt.2016.00026. eCollection 2016.

4.

Association between RGS4 variants and psychotic-like experiences in nonclinical individuals.

de Castro-Catala M, Cristóbal-Narváez P, Kwapil TR, Sheinbaum T, Peña E, Barrantes-Vidal N, Rosa A.

Eur Arch Psychiatry Clin Neurosci. 2017 Feb;267(1):19-24. doi: 10.1007/s00406-016-0676-7. Epub 2016 Feb 24.

PMID:
26910404
5.

Influence of DAOA and RGS4 genes on the risk for psychotic disorders and their associated executive dysfunctions: A family-based study.

Soler J, Miret S, Lázaro L, Parellada M, Martín M, Lera-Miguel S, Rosa A, de Castro-Catala M, Cuesta MJ, Fañanás L, Krebs MO, Fatjó-Vilas M.

Eur Psychiatry. 2016 Feb;32:42-7. doi: 10.1016/j.eurpsy.2015.11.002. Epub 2016 Jan 21.

PMID:
26803614
6.

Reciprocal Alterations in Regulator of G Protein Signaling 4 and microRNA16 in Schizophrenia.

Kimoto S, Glausier JR, Fish KN, Volk DW, Bazmi HH, Arion D, Datta D, Lewis DA.

Schizophr Bull. 2016 Mar;42(2):396-405. doi: 10.1093/schbul/sbv139. Epub 2015 Sep 30.

7.

Olanzapine Reversed Brain Gene Expression Changes Induced by Phencyclidine Treatment in Non-Human Primates.

Martin MV, Mirnics K, Nisenbaum LK, Vawter MP.

Mol Neuropsychiatry. 2015 Jul;1(2):82-93.

8.

Adenosine Receptors Differentially Regulate the Expression of Regulators of G-Protein Signalling (RGS) 2, 3 and 4 in Astrocyte-Like Cells.

Eusemann TN, Willmroth F, Fiebich B, Biber K, van Calker D.

PLoS One. 2015 Aug 11;10(8):e0134934. doi: 10.1371/journal.pone.0134934. eCollection 2015.

9.

Pharmacogenetics and antipsychotic treatment response.

Naumovska Z, Nestorovska AK, Filipce A, Sterjev Z, Brezovska K, Dimovski A, Suturkova LJ.

Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(1):53-67. Review.

PMID:
26076775
10.

Synergistic association of PI4KA and GRM3 genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of illness.

Kaur H, Jajodia A, Grover S, Baghel R, Jain S, Kukreti R.

Am J Med Genet B Neuropsychiatr Genet. 2014 Dec;165B(8):635-46. doi: 10.1002/ajmg.b.32268. Epub 2014 Sep 11.

PMID:
25209194
11.

Genetic variations of PIP4K2A confer vulnerability to poor antipsychotic response in severely ill schizophrenia patients.

Kaur H, Jajodia A, Grover S, Baghel R, Gupta M, Jain S, Kukreti R.

PLoS One. 2014 Jul 15;9(7):e102556. doi: 10.1371/journal.pone.0102556. eCollection 2014.

12.

Modification and functional inhibition of regulator of G-protein signaling 4 (RGS4) by 4-hydroxy-2-nonenal.

Monroy CA, Doorn JA, Roman DL.

Chem Res Toxicol. 2013 Dec 16;26(12):1832-9. doi: 10.1021/tx400212q. Epub 2013 Nov 14.

13.

RGS4 and COMT risk variants are associated with brain structural alterations.

Lener MS, Goodnow SJ, Wood JA, Chowdari KV, Keshavan MS, Nimgaonkar V, Prasad KM.

Schizophr Res. 2013 Oct;150(1):321-2. doi: 10.1016/j.schres.2013.07.013. Epub 2013 Jul 30. No abstract available.

PMID:
23911251
14.

Analysis of CpG SNPs in 34 genes: association test with suicide attempt in schizophrenia.

Bani-Fatemi A, Gonçalves VF, Zai C, de Souza R, Le Foll B, Kennedy JL, Wong AH, De Luca V.

Schizophr Res. 2013 Jul;147(2-3):262-8. doi: 10.1016/j.schres.2013.04.018. Epub 2013 May 14.

PMID:
23684163
15.

Polymorphisms in microRNA target sites influence susceptibility to schizophrenia by altering the binding of miRNAs to their targets.

Gong Y, Wu CN, Xu J, Feng G, Xing QH, Fu W, Li C, He L, Zhao XZ.

Eur Neuropsychopharmacol. 2013 Oct;23(10):1182-9. doi: 10.1016/j.euroneuro.2012.12.002. Epub 2013 Jan 16.

PMID:
23332465
16.

Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment.

Rivero G, Gabilondo AM, García-Sevilla JA, Callado LF, La Harpe R, Morentin B, Meana JJ.

Psychopharmacology (Berl). 2013 Mar;226(1):177-88. doi: 10.1007/s00213-012-2888-5. Epub 2012 Oct 24.

PMID:
23093381
17.

Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma.

Steiner J, Bernstein HG, Schiltz K, Müller UJ, Westphal S, Drexhage HA, Bogerts B.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:287-94. doi: 10.1016/j.pnpbp.2012.09.016. Epub 2012 Oct 17. Review.

PMID:
23085507
18.

Zebrafish rgs4 is essential for motility and axonogenesis mediated by Akt signaling.

Cheng YC, Scotting PJ, Hsu LS, Lin SJ, Shih HY, Hsieh FY, Wu HL, Tsao CL, Shen CJ.

Cell Mol Life Sci. 2013 Mar;70(5):935-50. doi: 10.1007/s00018-012-1178-z. Epub 2012 Oct 11.

PMID:
23052218
19.

Hypoxic induction of the regulator of G-protein signalling 4 gene is mediated by the hypoxia-inducible factor pathway.

Olechnowicz SW, Fedele AO, Peet DJ.

PLoS One. 2012;7(9):e44564. doi: 10.1371/journal.pone.0044564. Epub 2012 Sep 7.

20.

Brain vs behavior: an effect size comparison of neuroimaging and cognitive studies of genetic risk for schizophrenia.

Rose EJ, Donohoe G.

Schizophr Bull. 2013 May;39(3):518-26. doi: 10.1093/schbul/sbs056. Epub 2012 Apr 12.

Supplemental Content

Loading ...
Support Center